# A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

> **NCT01534052** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 52 (actual)

## Conditions studied

- Castration-Resistant Prostate Cancer (CRPC)

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT01534052
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-21
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-04-18
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534052, "A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01534052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*